| Identification | Back Directory | [Name]
RGFP 109 | [CAS]
1215493-56-3 | [Synonyms]
RG2833
RG-2833
RG 2833
RGFP109
CS-2320
RGFP-109
RGFP 109
RG2833(RGFP109)
RG2833; RGFP109; RG-2833; RGFP 109
N-[6-(2-aminoanilino)-6-oxohexyl]-4-methylbenzamide
N-[6-(2-Aminophenylamino)-6-oxohexyl]-4-methylbenzamide
Benzamide, N-[6-[(2-aminophenyl)amino]-6-oxohexyl]-4-methyl-
RGFP 109 N-[6-(2-Aminophenylamino)-6-oxohexyl]-4-methylbenzamide | [Molecular Formula]
C20H25N3O2 | [MDL Number]
MFCD25976845 | [MOL File]
1215493-56-3.mol | [Molecular Weight]
339.431 |
| Chemical Properties | Back Directory | [Boiling point ]
620.1±50.0 °C(Predicted) | [density ]
1.163±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
insoluble in H2O; ≥16.95 mg/mL in DMSO; ≥8.05 mg/mL in EtOH with gentle warming and ultrasonic | [form ]
Powder | [pka]
14.62±0.70(Predicted) |
| Hazard Information | Back Directory | [Uses]
RGFP 109 is a histone deacetylase (HDAC) inhibitor that has shown to reverse FXN gene silencing in short-term studies of Friedreich ataxia (FRDA) patient cells. | [target]
HDAC1 | [storage]
Store at -20°C |
|
|